Search research articles
Contact Us
Filters
Showing results (201-210 of 315) with videos related to
Page
of 32
Sort By:
Cancer Chemotherapy and Pharmacology
|
September 3, 2018
Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models
Udai Banerji, Nivedita Sain, Swee Y Sharp, et al.
Nucleic Acids Research
|
November 30, 2018
canSAR: update to the cancer translational research and drug discovery knowledgebase
Elizabeth A Coker, Costas Mitsopoulos, Joesph E Tym, et al.
Neoplasia (New York, N.Y.)
|
April 9, 2008
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts
Yuen-Li Chung, Helen Troy, Rebecca Kristeleit, et al.
Journal of the National Cancer Institute
|
May 4, 2006
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies
Paul Workman, Eric O Aboagye, Yuen-Li Chung, et al.
Journal of the National Cancer Institute
|
November 6, 2003
Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models
Yuen-Li Chung, Helen Troy, Udai Banerji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2019
Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer
Susan Slovin, Syed Hussain, Fred Saad, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 7, 2007
Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors
Masahiko Hayakawa, Hiroyuki Kaizawa, Hiroyuki Moritomo, et al.
BMC Research Notes
|
May 25, 2012
Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy
Loreta M Rodrigues, Yuen-Li Chung, Nada M S Al Saffar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 12, 2004
Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status
Zsofia Kote-Jarai, Richard D Williams, Nicola Cattini, et al.
Bioorganic & Medicinal Chemistry
|
January 11, 2011
Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements
Jonathan M Large, Jane E Torr, Florence I Raynaud, et al.
Page
of 32
Search research articles
Search
Showing results (201-210 of 315) with videos related to
Sort By:
Page
of 32
Cancer Chemotherapy and Pharmacology
|
September 3, 2018
Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models
Udai Banerji, Nivedita Sain, Swee Y Sharp, et al.
Nucleic Acids Research
|
November 30, 2018
canSAR: update to the cancer translational research and drug discovery knowledgebase
Elizabeth A Coker, Costas Mitsopoulos, Joesph E Tym, et al.
Neoplasia (New York, N.Y.)
|
April 9, 2008
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts
Yuen-Li Chung, Helen Troy, Rebecca Kristeleit, et al.
Journal of the National Cancer Institute
|
May 4, 2006
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies
Paul Workman, Eric O Aboagye, Yuen-Li Chung, et al.
Journal of the National Cancer Institute
|
November 6, 2003
Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models
Yuen-Li Chung, Helen Troy, Udai Banerji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2019
Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer
Susan Slovin, Syed Hussain, Fred Saad, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 7, 2007
Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors
Masahiko Hayakawa, Hiroyuki Kaizawa, Hiroyuki Moritomo, et al.
BMC Research Notes
|
May 25, 2012
Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy
Loreta M Rodrigues, Yuen-Li Chung, Nada M S Al Saffar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 12, 2004
Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status
Zsofia Kote-Jarai, Richard D Williams, Nicola Cattini, et al.
Bioorganic & Medicinal Chemistry
|
January 11, 2011
Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements
Jonathan M Large, Jane E Torr, Florence I Raynaud, et al.
Page
of 32